about
Screening for hotspot mutations in PI3K, JAK2, FLT3 and NPM1 in patients with myelodysplastic syndromes.Stathmin 1 inhibition amplifies ruxolitinib-induced apoptosis in JAK2V617F cellsPTK2 and PTPN11 expression in myelodysplastic syndromes.ANKHD1, a novel component of the Hippo signaling pathway, promotes YAP1 activation and cell cycle progression in prostate cancer cells.ARHGAP21 is a RhoGAP for RhoA and RhoC with a role in proliferation and migration of prostate adenocarcinoma cells.Knockdown of insulin receptor substrate 1 reduces proliferation and downregulates Akt/mTOR and MAPK pathways in K562 cells.ANKHD1 silencing inhibits Stathmin 1 activity, cell proliferation and migration of leukemia cells.BNIP3L in myelodysplastic syndromes and acute myeloid leukemia: impact on disease outcome and cellular response to decitabine.Simvastatin abrogates inflamed neutrophil adhesive properties, in association with the inhibition of Mac-1 integrin expression and modulation of Rho kinase activity.Hematopoietic defects in response to reduced Arhgap21.Natural Type II Collagen Hydrogel, Fibrin Sealant, and Adipose-Derived Stem Cells as a Promising Combination for Articular Cartilage Repair.Reduced expression of NR4A1 activates glycolytic pathway in acute promyelocytic leukemia cells.FMNL1 promotes proliferation and migration of leukemia cells.Effects of thalidomide on long-term bone marrow cultures from patients with myelodysplastic syndromes: induction of IL-10 expression in the stromal layers.Stathmin 1 is involved in the highly proliferative phenotype of high-risk myelodysplastic syndromes and acute leukemia cells.Depletion of ZBTB38 potentiates the effects of DNA demethylating agents in cancer cells via CDKN1C mRNA up-regulationEffects of RhoA and RhoC upon the sensitivity of prostate cancer cells to glutamine deprivationBRD4 Inhibition Enhances Azacitidine Efficacy in Acute Myeloid Leukemia and Myelodysplastic SyndromesUpdates on DNA methylation modifiers in acute myeloid leukemia
P50
Q35028968-DC79B73A-33A9-4190-9B30-30CAEC06FA99Q36557368-45A83F6F-05F3-4C07-9912-9F519B707694Q37234608-1B04D417-AC2C-4BBD-9CB7-1CE34ABB262DQ39004834-2475878F-1025-4888-885C-B06286CE95D3Q39234913-2C5DF07F-632C-4D36-A5A1-4A2073D16AA1Q39543191-8F7652F2-1C1A-4F9E-A9C0-7F5FE9F8166CQ41671217-D1EB603E-FCE9-4542-93B7-16572FBC24EEQ42362055-E5EBD8E7-5837-4BA7-9867-C9F1E600264DQ46017785-929536DC-BC41-4C1A-84F8-BF744D0CFB7EQ47280922-8B471702-285D-4B34-AE1C-6C43AE00993CQ47936532-B1B2640B-3869-487E-A55B-7113FE8EA4EEQ48174492-C7D30575-E8BC-4E53-8C68-4AA4B3E7378BQ50337087-26619FFF-4C01-4281-8CF9-B6781DEDBBB4Q54376607-D451655F-4ABC-4AAF-BCF8-B8968C0270FDQ54416532-A182ADFB-5C4F-435A-B1EA-9078DF617322Q57476629-A4625C5D-0075-4ED6-8F95-187AA9FBA8C5Q60482388-F7FF6F24-8C78-42E4-9DA2-CD202503FC8CQ61807137-2BABBBAE-0E91-45A0-8DA2-CE3350E5750FQ89562928-E29A6BC6-E2CD-4E81-A64B-93777514DBE0
P50
description
hulumtuese
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Mariana Lazarini
@ast
Mariana Lazarini
@en
Mariana Lazarini
@es
Mariana Lazarini
@fr
Mariana Lazarini
@nl
Mariana Lazarini
@sl
Mariana Lazarini
@sq
type
label
Mariana Lazarini
@ast
Mariana Lazarini
@en
Mariana Lazarini
@es
Mariana Lazarini
@fr
Mariana Lazarini
@nl
Mariana Lazarini
@sl
Mariana Lazarini
@sq
prefLabel
Mariana Lazarini
@ast
Mariana Lazarini
@en
Mariana Lazarini
@es
Mariana Lazarini
@fr
Mariana Lazarini
@nl
Mariana Lazarini
@sl
Mariana Lazarini
@sq
P106
P21
P31
P496
0000-0002-5030-7583